when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

ELI LILLY CO · news · pharmadog

← back to ELI LILLY CO

News mentioning ELI LILLY CO

630 stories

Jul 23, 26STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and morestat

Jul 23, 26STAT+: FDA is urged by advocacy group to ban DTC prescription drug adsstat

Jul 23, 26Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 databiospace

Jul 23, 26Roche's late stage pipeline 'so full,' CEO Schinecker not feeling pressure to add onbiospace

Jul 23, 26Lilly's triple agonist heads to regulators after two more Phase 3 obesity winsendpoints

Jul 23, 26STAT+: New data on Eli Lilly’s ‘triple-G’ drug leave open questions on heart benefitstat

Jul 23, 26Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clearfiercebiotech

Jul 23, 26Make or break: Commercial hires critical for successbiospace

Jul 23, 26Biopharma layoffs must double in H2 for 2026 to match 2025 cutsbiospace

Jul 22, 26Webinar: From Clinical to Commercial: Talent Strategies for Biopharma Growthbiospace

Jul 22, 26Q&A: Lilly returns to neuropsych and looks ahead to Alzheimer's preventionendpoints

Jul 22, 26STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and morestat

Jul 22, 26US ‘eroding’ lead in rare diseases a matter of national security: Reportbiospace

Jul 22, 26Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2biospace

Jul 22, 26AI data becomes sticking point in biopharma dealmakingbiospace

Jul 21, 26Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug dosesendpoints

Jul 21, 26Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesitybiospace

Jul 21, 26Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugsbiopharma dive

Jul 21, 26Dimension restocks with $800M to capitalize on AI’s ‘rapid ascent’biopharma dive

Jul 21, 26STAT+: Anthropic deepens work with rare disease drugsstat

Jul 21, 26STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and morestat

Jul 21, 26Novartis stays 'geography-agnostic' in dealmaking amid flurry of China dealsbiospace

Jul 21, 26‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx dealfiercebiotech

Jul 21, 26STAT+: Nabla’s new CEO on plan to gain market share in a competitive AI scribe environmentstat

Jul 21, 26STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’stat

Jul 21, 26Jupiter enters psychedelics space with $100M deal for PharmAla's MDMA drugfiercebiotech

Jul 20, 26Pain drugmaker Latigo outlines plans to go publicbiopharma dive

Jul 20, 26Lilly’s AtaiBeckley buy validates space as Big Pharma takes note of psychedelicsbiospace

Jul 20, 26J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B dealendpoints

Jul 20, 26STAT+: A most-wanted fugitive appears to have been secretly working as a biotech executivestat

← prevpage 15 of 21next →